Abstract 16078: SEEQ Mobile Cardiac Telemetry Associated With a High Yield of Clinically Relevant Arrhythmias in Patients With Suspected Arrhythmia
Introduction: External cardiac monitoring through mobile cardiac telemetry (MCT) is frequently used to identify and monitor suspected arrhythmias for up to 30 days. The SEEQ™ MCT offers up to 4 weeks of continuous, 24 hour live monitoring for clinically relevant arrhythmias in a simple, patch design.
Hypothesis: Cardiac monitoring with the SEEQ™ MCT has a high arrhythmia detection rate and compliance rate with up to 4 weeks of monitoring.
Methods: Patients indicated for MCT were enrolled in the SEEQ™ Performance study; a prospective, non-randomized, multi-center clinical study. Patients received between 1-4 weeks of MCT monitoring based on physician prescription. Clinically relevant arrhythmias (CRA) included, but were not limited to ventricular tachycardia/fibrillation, bradycardia, pause >2 sec, 2nd and 3rd degree AV block, Atrial fibrillation/flutter, SVT, PVCs (>6 in 45 sec) or patient triggered events. Detection rates were collected along with patient compliance and satisfaction during the study.
Results: One hundred eighty-two patients underwent MCT monitoring with the SEEQ device (mean age of 73.8 ±10.4 years and 51.6% (n=94) female). The most common cardiovascular disease was hypertension (77.5%, 141) with 30 (16.5%) having a history of unexplained syncope, 10 (5.5%) cryptogenic stroke and 17 (9.3%) a transient ischemic attack. Previous cardiac monitoring was performed in 75.3% (137) of the patients with an average of 1.7 ± 1.2 tests per patient. The SEEQ™ MCT identified 80.8% (n=147) of monitored patients with at least 1 CRA. The primary CRAs detected were PVCs >6 in 45 secs (43.4%, 79), Sinus Brady (33.5%, 61) and atrial fibrillation (31.9%, 58). Detection rates increased with length of monitoring prescribed (with the majority of physicians prescribing 4 week monitoring) from 40.0% (2/5), 73.1% (38/52), 78.6% (11/14), to 86.5% (96/111) at 1, 2, 3 and 4 weeks respectively. Overall, 90.1% (164/182) of patients completed their prescribed monitoring and 82.5% of patients were satisfied with the SEEQ device and 89.0% would recommend the device.
Conclusion: External cardiac monitoring up to 30 days with SEEQ™ MCT is associated with a high detection rate of clinically relevant arrhythmias and a high patient compliance and satisfaction rate.
Author Disclosures: S. Shareghi: None. M. Tavakol: Honoraria; Significant; Novartis. K. Lindborg: Employment; Significant; Medtornic, Plc. C. Alfaro Vives: Employment; Significant; Medtronic, Plc. L. Spaccavento: None.
- © 2016 by American Heart Association, Inc.